Aclarion, Inc (ACON) Fair Value & Analysis
Healthcare · US · Market cap $7.1M
Aclarion, Inc
ACON · US
Fair value as of: Jul 14, 2026
From 3 valuation models · updated today
Share price −13.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.36 – $9.69 · fair‑value band $0.8740 – $2.47 · the $2.69 price screens above the $1.68 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aclarion, Inc (ACON) currently trades at $2.69, while our model-based Fair Value estimate is $1.68 — implying the stock looks roughly 37.4% overvalued today. We read business quality at 16/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $77.9K. Revenue grew 11.3% year over year. It earns a return on equity of -45.4%. The balance sheet holds a net cash position of $12.0M. Fundamentals as of Jul 14, 2026
Our scenario range runs from $0.8740 (bear case) to $2.47 (bull case); at $2.69, the current price sits above that range. The share trades about 78% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -39% fair-value upside — at -37%, ACON screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aclarion, Inc reported revenue of $75.7K in FY2025 versus $60.3K in FY2021, a compound +5.9%/yr. Reported net income was −$7.2M in FY2025.
Is ACON fairly valued? → Check now
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $163.76 | $103.58 | -37% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $57.40 | $23.87 | -58% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $89.72 | $54.47 | -39% |
| Hinge Health, Inc HNGE | $70.38 | $31.17 | -56% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
| Ping An Healthcare and Technology Company PANHF | $0.9000 | $0.5700 | -37% |
| 10x Genomics, Inc TXG | $32.94 | $22.67 | -31% |
| XtalPi Holdings 2228 | HK$7.48 | HK$1.03 | -86% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aclarion, Inc (ACON) undervalued?
What is the fair value of ACON?
What is the quality score of ACON?
What is the revenue of Aclarion, Inc (ACON)?
What is the net profit margin of ACON?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Aclarion, Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.